In summary, we, for the first time, revealed that elevated GLIS1 expression in patient-derived CAFs of OSCs with metastatic potential, and that silencing GLIS1 in mCAFs reduced motility, adhesion, angiogenesis, and metastasis of ovarian cancer cells in vitro and in vivo. This evidence concerns the gene GLIS1 and ovarian cancer.